Patents by Inventor David C Hunden

David C Hunden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-peptidyl vasopressin V1A antagonists
    Patent number: 6610680
    Abstract: This invention provides substituted 2-(azetidinon-1-yl) acetic acid derivatives of Formula II for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 26, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6521611
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Non-peptidyl vasopressin V1a antagonists
    Publication number: 20020049187
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I 1
    Type: Application
    Filed: December 8, 2000
    Publication date: April 25, 2002
    Inventors: Robert F. Bruns, Robin DG Cooper, Bruce A. Dressman, David C. Hunden, Stephen W. Kaldor, Gary A. Koppel, John R. Rizzo, Jeffrey J. Skelton, Mitchell I. Steinberg
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6204260
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: March 20, 2001
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin DG Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Combinatorial process for synthesizing azetidinone analogs
    Patent number: 5759865
    Abstract: This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 2, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Michael O. Chaney, Robin D. Cooper, David C. Hunden, Gary A. Koppel, Jeffrey J. Skelton
  • Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
    Patent number: 5716975
    Abstract: Provided are methods for treating hyperglycemia and Alzheimer's disease utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant methods are novel and, accordingly, such compounds and pharmaceutical formulations thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: Juliana M. Bue-Valleskey, David C. Hunden, Charles D. Jones, Jill A. Panetta, Walter N. Shaw
  • Hypoglycemic agents
    Patent number: 5661168
    Abstract: Provided is a method for treating hyperglycemia utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant method are novel and, accordingly, such compounds and pharmaceutical formulations thereof, are also provided.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Juliana Bue-Valleskey, David C. Hunden, Charles D. Jones, Walter N. Shaw
  • Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
    Patent number: 5523314
    Abstract: Provided are methods for treating hyperglycemia and Alzheimer's disease utilizing certain rhodanine derivatives. Certain of the rhodanine derivatives utilized in the instant methods are novel and, accordingly, such compounds and pharmaceutical formulations thereof are also provided.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: June 4, 1996
    Assignee: Eli Lilly and Company
    Inventors: Juliana M. Bue-Valleskey, David C. Hunden, Charles D. Jones, Jill A. Panetta, Walter N. Shaw
  • Serotonin and norepinephrine uptake inhibitors
    Patent number: 4902710
    Abstract: The present invention provides propanamines, substituted at the 3-position of the propanamine chain with a thio, sulfinyl or sulfonyl moiety, which are capable of selectively inhibiting the uptake of serotonin and norepinephrine.
    Type: Grant
    Filed: December 14, 1988
    Date of Patent: February 20, 1990
    Assignee: Eli Lilly and Company
    Inventors: Bennie J. Foster, David C. Hunden, Edward R. Lavagnino
  • Thienothienylglycyl cephalosporin derivatives
    Patent number: 4581352
    Abstract: 7-(Thienothienyl)glycylamido cephalosporins have good gram positive activity and favorable pharmacokinetics and are orally effective.
    Type: Grant
    Filed: December 3, 1984
    Date of Patent: April 8, 1986
    Assignee: Eli Lilly and Company
    Inventors: Bennie J. Foster, David C. Hunden, Edward R. Lavagnino